http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Prediction of Prognosis in Glioblastoma Using Radiomics Features of Dynamic Contrast-Enhanced MRI
Pak Elena,Choi Kyu Sung,Choi Seung Hong,Park Chul-Kee,김태민,Park Sung-Hye,Lee Joo Ho,Lee Soon-Tae,Hwang Inpyeong,Yoo Roh-Eul,Kang Koung Mi,Yun Tae Jin,Kim Ji-hoon,Sohn Chul-Ho 대한영상의학회 2021 Korean Journal of Radiology Vol.22 No.9
Objective: To develop a radiomics risk score based on dynamic contrast-enhanced (DCE) MRI for prognosis prediction in patients with glioblastoma. Materials and Methods: One hundred and fifty patients (92 male [61.3%]; mean age ± standard deviation, 60.5 ± 13.5 years) with glioblastoma who underwent preoperative MRI were enrolled in the study. Six hundred and forty-two radiomic features were extracted from volume transfer constant (Ktrans), fractional volume of vascular plasma space (Vp), and fractional volume of extravascular extracellular space (Ve) maps of DCE MRI, wherein the regions of interest were based on both T1- weighted contrast-enhancing areas and non-enhancing T2 hyperintense areas. Using feature selection algorithms, salient radiomic features were selected from the 642 features. Next, a radiomics risk score was developed using a weighted combination of the selected features in the discovery set (n = 105); the risk score was validated in the validation set (n = 45) by investigating the difference in prognosis between the “radiomics risk score” groups. Finally, multivariable Cox regression analysis for progression-free survival was performed using the radiomics risk score and clinical variables as covariates. Results: 16 radiomic features obtained from non-enhancing T2 hyperintense areas were selected among the 642 features identified. The radiomics risk score was used to stratify high- and low-risk groups in both the discovery and validation sets (both p < 0.001 by the log-rank test). The radiomics risk score and presence of isocitrate dehydrogenase (IDH) mutation showed independent associations with progression-free survival in opposite directions (hazard ratio, 3.56; p = 0.004 and hazard ratio, 0.34; p = 0.022, respectively). Conclusion: We developed and validated the “radiomics risk score” from the features of DCE MRI based on non-enhancing T2 hyperintense areas for risk stratification of patients with glioblastoma. It was associated with progression-free survival independently of IDH mutation status.
Antitumor effects of herbal mixture extract in the pancreatic adenocarcinoma cell line PANC1
Pak, Pyo June,Kang, Beob Hwa,Park, Sung Hyo,Sung, Ji Hyun,Joo, Yong Hoon,Jung, Seung Hyun,Chung, Namhyun NATIONAL HELLENIC RESEARCH FOUNDATION 2016 ONCOLOGY REPORTS Vol.36 No.5
<P>A recent study showned that complementary medicine is gradually gaining wide acceptance. In the present study, the herbal mixture extract (H3) composed of 3 oriental herbal plants was investigated for anticancer activity in vitro and in vivo. H3 inhibited PANC1 cell growth by promoting G0/G1 arrest (11% increase) and apoptotic cell death (9% increase). H3 also suppressed stem cell-like side population cells (4% decrease) and migration activity (24% decrease). In contrast, gemcitabine decreased side population cells and migration activity by 3 and 11%, respectively. These effects of H3 and gemcitabine were further studied by examining the expression of apoptosis-associated genes (CXCR4, JAK2 and XIAP) and stem cell-associated genes (ABCG2, POU5F1 and SOX2). We also found that H3 suppressed tumor growth by 46% in a PANC1-xenograft model, while gemcitabine caused a 36% decrease. The antitumor effects of H3 were confirmed by western blot analysis for COX-2 and cytochrome c expression. Furthermore, necrotic cell death and erythrocyte-containing cavities were detected in tumor tissue by hematoxylin and eosin (H&E) staining. Notably, the combinatorial therapy (H3 and gemcitabine) increased tumor growth compared to that in the control. In conclusion, the present study shows that H3 has promise as a therapeutic agent against pancreatic cancer and its cancer stem cells.</P>
Pak, Kyung Ho,Hyung, Woo Jin,Son, Taeil,Obama, Kazutaka,Woo, Yanghee,Kim, Hyoung-Il,An, Ji Yeong,Kim, Jong Won,Cheong, Jae-Ho,Choi, Seung Ho,Noh, Sung Hoon Springer International 2012 Surgical endoscopy Vol.26 No.1
<P>Although many reports have indicated the feasibility of laparoscopic gastrectomy (LG) regarding short-term surgical outcomes, the role of LG remains controversial because studies of long-term outcomes of LG are insufficient. The purpose of this study was to evaluate the long-term oncologic outcomes of patients who have undergone LG.</P>
Lee, Seung-Hyun,Kang, Dae Ryong,Uhm, Jae-Sun,Shim, Jaemin,Sung, Jung-Hoon,Kim, Jong-Youn,Pak, Hui-Nam,Lee, Moon-Hyoung,Joung, Boyoung Elsevier 2014 American Heart Journal Vol.167 No.4
<P>Background New-onset postoperative atrial fibrillation (POAF) is associated with poor short- and long-term outcomes after isolated coronary artery bypass graft (CABG). This study evaluated whether new-onset POAF is independently associated with long-term (> 1 year) atrial fibrillation (AF) and mortality. Methods Among 1,171 consecutive patients who had undergone CABG, AF and mortality were compared between patients with POAF (POAF group, n = 244) and those without POAF (no-POAF group, n = 927) after propensity score matching. Results During the follow-up period of 41 +/- 23 months (range 0-87 months), the POAF group had a higher incidence of total (20/927 [2.2%] vs 46/244 [18.9%], P < .001) and long-term AF recurrence (13/927 [1.4%] vs 25/ 244 [10.2%], P b.001). Even after propensity score matching, the POAF group still showed a higher incidence of total (7/244 [2.9%] vs 46/224 [18.9%], P < .001) and long-term AF recurrence (4/244 [1.6%] vs 25/224 [10.2%], P < .001). In addition, the POAF group had a lower cumulative survival free of long-term AF than the no-POAF group (P < .001). In competing risk regression, POAF was an independent predictor of long-term newly developed AF (hazard ratio 4.99, 95% CI 1.68-14.84, P = .004). Cumulative survival free of death was worse in patients with POAF (P = .01). Conclusions New-onset POAF was shown to be a predictor of long-term newly developed AF in CABG patients. The results of this study suggest that patients who develop POAF should undergo strict surveillance and routine screening for AF during follow-up after surgery.</P>
Lee, Seung-Jun,Sung, Jung-Hoon,Kim, Jin-Bae,Ahn, Min-Soo,Lee, Hye Young,Uhm, Jae-Sun,Pak, Hui-Nam,Lee, Moon-Hyoung,Kim, Jong-Yun,Joung, Boyoung Wolters Kluwer Health 2016 Medicine Vol.95 No.47
<▼1><P>Supplemental Digital Content is available in the text</P></▼1><▼2><P><B>Abstract</B></P><P>This study aimed to evaluate the safety and efficacy of vitamin K antagonist (VKA) in atrial fibrillation (AF) patients with previous ulcer bleeding.</P><P>In this multicenter, retrospective analysis, clinical outcomes of 754 AF patients with a history of ulcer bleeding were evaluated. After ulcer treatment, 458 patients (61%) were treated with VKA, and the outcomes were compared to 296 patients (39%) without VKA.</P><P>VKA treatment significantly increased major bleeding (7.3%/year vs 3.2%/year, <I>P</I> < 0.001), and reduced major adverse cardiac events (MACE) (5.4%/year vs 10.0%/year, <I>P</I> < 0.001). Specifically, risk of gastrointestinal bleeding was significantly higher in the VKA group than no-VKA group (5.7%/year vs 2.6%/year, <I>P</I> < 0.001). Consequently, there was no difference in the incidence of composite of a MACE and major bleeding, between the 2 groups. In patients with time in the therapeutic range (TTR) ≥65%, VKA significantly decreased MACE (2.8%/year vs 10.0%/year, <I>P</I> < 0.001) without increasing major bleeding. Net clinical benefit model showed beneficial effects of VKA in patients with TTR ≥65%, and harmful effects in those with TTR < 55%.</P><P>In AF patients with previous ulcer bleeding, VKA treatment did not improve clinical outcomes unless the international normalized ratio level was constantly maintained (TTR ≥65%), as the gastrointestinal bleeding (GIB) risk significantly increased.</P></▼2>
인공지능 기반의 임상연구를 위한 의료 데이터 셋 관리 시스템
박민기 ( Min-gi Pak ),한성민 ( Seong-min Han ),김승진 ( Seung-jin Kim ),이충서 ( Tae-hoon Kim ),김태훈 ( Chung-sub Lee ),정창원 ( Chang-won Jeong ),윤권하 ( Kwon-ha Yoon ) 한국정보처리학회 2019 한국정보처리학회 학술대회논문집 Vol.26 No.2
본 논문은 국제표준화인 OHDSI OMOP-CDM 의 확장으로 의료영상 표준기반으로 한 관리시스템에 대해 기술한다. 이를 위해 기존 공통데이터모델과 연계에 중점을 두어 DICOM 메타태그정보 기반의 의료영상 표준 모델의 스키마를 제시한다. 이를 기반으로 머신러닝 기술개발을 위한 데이터 셋 생성과 관리를 위한 웹 기반 시스템 구조와 기능에 대해서 기술한다. 끝으로 구현된 시스템에서 제공하는 웹 서비스 수행 결과를 보인다.
( Chi Hong Kim ),( Seung Hoon Kim ),( Sonya Youngju Pak ),( Jin Young Yoo ),( Sung Kyoung Kim ),( Hoon Kyo Kim ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Recently, mutation-specifi c antibodies have been developed for detecting epidermal growth factor receptor (EGFR) mutations by immunohistochemistry (IHC). This study was designed to determine the signifi cance of the type of specimen used for analysis (biopsy vs. resection), and to evaluate any correlation between mutation- specifi c antibodies and total EGFR protein (tEGFR) expressions. Methods: IHC using mutation-specifi c antibodies for E746-A750 deletion (DEL) and L858R point mutation (L858R) was performed in biopsies or tissue microarrays (TMA) of resected tumors from a total of 154 patients with lung adenocarcinoma. tEGFR was also investigated by IHC. Results were then compared with DNA sequencing data. Results: Molecular-based assays detected EGFR mutations in 62 (40.3%) patients, including 14 (9.1%) with DEL, and 31 (20.1%) with L858R. IHC with two mutation-speci fi c antibodies demonstrated a homogeneous staining pattern, and showed overall (biopsy/resection) sensitivity, specifi city, positive predictive value (PPV), and negative predictive value (NPV) of 75.6% (78.3%/72.7%), 94.5 % (90.9%/96.3%), 85% (78.3%/88.9%), and 90.4% (90.9%/89.7%), respectively. tEGFR showed low sensitivity, specifi city, PPV, and NPV, with no correlation with either DEL-specifi c or L858R-speci fi c antibodies. Conclusions: IHC using EGFR mutation-specific antibodies proved to be a reliable screening tool for identifying EGFR mutations in both biopsied and resected specimens with pulmonary adenocarcinoma, especially when the tumor cells in biopsy samples are not suffi cient for molecular biology techniques.